Agios_2021_Logo.png
Agios Reports Business Highlights and Third Quarter 2023 Financial Results
November 02, 2023 07:00 ET | Agios Pharmaceuticals, Inc.
– First Patient Dosed in Phase 3 Portion of the RISE UP Pivotal Study of Mitapivat in Sickle Cell Disease – – Completed Enrollment in Phase 3 ACTIVATE-KidsT Pediatric Study of Mitapivat in PK...
Agios_2021_Logo.png
Agios to Webcast Conference Call of Third Quarter 2023 Financial Results on Nov. 2, 2023
October 19, 2023 07:00 ET | Agios Pharmaceuticals, Inc.
Agios to Webcast Conference Call of Third Quarter 2023 Financial Results on Nov. 2, 2023
Agios_2021_Logo.png
Agios to Present at the Morgan Stanley Global Healthcare Conference on September 12, 2023
August 29, 2023 07:00 ET | Agios Pharmaceuticals, Inc.
CAMBRIDGE, Mass., Aug. 29, 2023 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in the field of cellular metabolism pioneering therapies for rare diseases, today announced...
Agios_2021_Logo.png
Agios Reports Business Highlights and Second Quarter 2023 Financial Results
August 03, 2023 06:35 ET | Agios Pharmaceuticals, Inc.
Announced Positive Results from Phase 2 Portion of the RISE UP Pivotal Study of Mitapivat in Sickle Cell Disease; On Track to Enroll First Patient in Phase 3 Portion of the Study in Q4 2023 ...
Agios_2021_Logo.png
Agios Announces Exclusive Worldwide License Agreement for Novel siRNA for the Potential Treatment of Polycythemia Vera
August 03, 2023 06:30 ET | Agios Pharmaceuticals, Inc.
– Preclinical siRNA Targeting TMPRSS6 is a Potential Disease-Modifying Treatment for Polycythemia Vera – – Agreement Combines Agios’ Scientific Expertise and Capabilities in Rare Hematologic Diseases...
Agios_2021_Logo.png
Agios to Webcast Conference Call of Second Quarter 2023 Financial Results on Aug. 3, 2023
July 13, 2023 07:00 ET | Agios Pharmaceuticals, Inc.
CAMBRIDGE, Mass., July 13, 2023 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in the field of cellular metabolism pioneering therapies for rare diseases, today announced...
Agios_2021_Logo.png
Agios Announces Positive Results from Phase 2 Portion of RISE UP Pivotal Study in Sickle Cell Disease with Both Mitapivat Dose Arms Achieving Statistically Significant Hemoglobin Response
June 26, 2023 06:30 ET | Agios Pharmaceuticals, Inc.
– Study’s Primary Efficacy Endpoint Achieved, with 46.2% of Patients in the 50 mg BID Mitapivat Arm and 50.0% of Patients in the 100 mg BID Mitapivat Arm Achieving a Hemoglobin Response, Compared to...
Agios_2021_Logo.png
Agios to Present at the Goldman Sachs Global Healthcare Conference on June 15, 2023
June 05, 2023 07:00 ET | Agios Pharmaceuticals, Inc.
CAMBRIDGE, Mass., June 05, 2023 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in the field of cellular metabolism pioneering therapies for rare diseases, today announced...
Agios_2021_Logo.png
Agios Appoints Catherine Owen to Board of Directors
May 25, 2023 07:00 ET | Agios Pharmaceuticals, Inc.
– John Maraganore Completes Tenure on Agios Board After Nearly a Dozen Years of Service – – Kaye Foster to Be Appointed Lead Independent Director – CAMBRIDGE, Mass., May 25, 2023 (GLOBE...
Agios_2021_Logo.png
Agios to Present Clinical and Translational Data at European Hematology Association Annual Congress
May 11, 2023 10:00 ET | Agios Pharmaceuticals, Inc.
– Agios to Present New Analyses from ACTIVATE, ACTIVATE-T and Long-Term Extension Studies in Adults with PK Deficiency Reinforcing Clinical Benefit of PYRUKYND® (mitapivat) on Hemoglobin, Hemolysis,...